Forbion Capital Partners has closed its third main fund at $208m, attracting commitments from Charles River Laboratories, Knight Therapeutics and unnamed insurance providers.

Less than six months after it was founded, China-based iCarbonX has completed a round featuring Tencent and Vcanbio that values it at $1bn.

Two Japanese universities sign a licensing agreement with immunology and microbiology company Vedanta to discover potential treatments for infectious diseases and cancer.

Henery Crown and Company joined the Brazil-based medical device and diagnostics equipment supplier for a series C round that boosted its total funding to $47m.

The corporate is in the early stages of setting up an India-based corporate venturing unit that will fund local healthcare technology startups.

UCB and Roche were among the investors in a Deerfield Management-led series B round that pushed the orphan disease treatment developer's total VC funding to $48m.

Aeglea Biotherapeutics, which is developing amino acid-targeted cancer and metabolic disease treatments, had raised $53.5m in VC funding from investors including Novartis and Eli Lilly.

Small molecule cancer drug developer Metabomed raised the cash from investors including Technion, Pfizer, Boehringer Ingelheim and co-founder MS Ventures.

Small molecule cancer drug developer Metabomed raised the cash from investors including Pfizer, Boehringer Ingelheim and co-founder MS Ventures.